Skip to main content
SpringerLink
Log in

Impact of erythropoietin treatment on the quality of life of oncologic patients

  • Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Anaemia has a high incidence in cancer patients, especially when it is a consequence of myelosuppressive treatments. The incidence and prevalence of this condition is influenced by the type and extension of the tumour, type and intensity of the myelosuppressive treatment that patients receive, and previous surgery or intercurrent infections. Clinical manifestations of anaemia, overlapped by tumour symptomatology, depend on haemoglobin (Hb) levels; these manifestations cause impairment of the functional capacity, as well as a negative impact on the quality of life (QOL) of cancer patients as a consequence. Erythropoietin treatment for anaemia has been established as optimal for correcting Hb levels. Its impact on patients’ QOL has been evaluated in numerous randomised prospective studies by the use of diverse types of erythropoietin and administration moes. The three types of erythropoietin, alpha, beta and darbepoetin alpha, have shown a clear efficacy in all haematological parameters. This positive effect is related with significant improvements in the QOL of patients, especially those patients undergoing myelosuppressive treatments, and with regard to specific scales of fatigue and anaemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Groopman JE, Itri LM (1999) Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634

    Article  PubMed  CAS  Google Scholar 

  2. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anaemia in cancer: a systematic review of the literature. Am J Med 116[Suppl 7A]:11S–26S

    Article  PubMed  Google Scholar 

  3. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306

    Article  PubMed  Google Scholar 

  4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43–46650

    PubMed  CAS  Google Scholar 

  5. Crawford J, Cella D, Cleeland C et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemia cancer patients receiving epoetin alfa therapy. Cancer 95:888–895

    Article  PubMed  CAS  Google Scholar 

  6. Cella D, Kallich J, McDermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986

    Article  PubMed  CAS  Google Scholar 

  7. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258–270

    Article  PubMed  CAS  Google Scholar 

  8. Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14:511–519

    Article  PubMed  CAS  Google Scholar 

  9. Jones M, Schenkel B, Just J, Fallowfield L (2004) Epoetin alfa improves quality of life in patients with cancer: results of a metaanalysis. Cancer 101:1720–1732

    Article  PubMed  CAS  Google Scholar 

  10. Gascon P (2005) Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer 41:2601–2612

    Article  PubMed  CAS  Google Scholar 

  11. Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response of tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425

    PubMed  CAS  Google Scholar 

  12. Ludwig H, Strasser K (2001) Symptomatology of anemia. Semin Oncol 28[Suppl 8]:7–14

    Article  PubMed  CAS  Google Scholar 

  13. Stone P, Richards M, A’Hern R et al (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11:561–567

    Article  PubMed  CAS  Google Scholar 

  14. Curt G, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353–360

    Article  PubMed  CAS  Google Scholar 

  15. Carulla J, Escobar Y, Montalar J et al (2005) Estudio epidemiológico sobre la prevalencia de la astenia en pacientes oncológicos. Clin Transl Oncol 7[Suppl 1]:1–158

    Google Scholar 

  16. Yellen SB, Cella DF, Webster KA et al (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy Measurement System. J Pain Symptom Manage 13:63–74

    Article  PubMed  CAS  Google Scholar 

  17. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19

    PubMed  CAS  Google Scholar 

  18. Holzner B, Kemmler G, Greil R et al (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13:965–973

    Article  PubMed  CAS  Google Scholar 

  19. Cella D, Dobrez D, Glaspy J (2003) Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14:511–519

    Article  PubMed  CAS  Google Scholar 

  20. Cella D, Eton D, Lai J et al (2002) Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manage 24:547–561

    Article  PubMed  Google Scholar 

  21. Kallich J, Tchekmedyian NS, Damiano A et al (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology 16[Suppl 9]:117–124

    PubMed  Google Scholar 

  22. O’shaughenessy JA (2003) Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer 4[Suppl 2]:S89–S94

    Article  Google Scholar 

  23. Mancuso A, Migliorino M, De Santis S et al (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17:146–150

    Article  PubMed  CAS  Google Scholar 

  24. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107

    Article  PubMed  CAS  Google Scholar 

  25. Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    PubMed  CAS  Google Scholar 

  26. Bottomley A, Thomas R, Van Steen K et al (2003) Guidelines for the use of epoetin: have quality-of-life benefits been proven? J Clin Oncol 21:2223–2224

    Article  PubMed  Google Scholar 

  27. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882

    PubMed  CAS  Google Scholar 

  28. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617

    Article  PubMed  CAS  Google Scholar 

  29. Chang J, Coutre F, Young S et al (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 12:2597–2605

    Google Scholar 

  30. Savonije JH, Groeningen CJ, Wormhoudt LW et al (2006) Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11:206–216

    Article  PubMed  CAS  Google Scholar 

  31. Savonije JH, van Groeningen CJ, van Bochove A et al (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 41: 1560–1569

    Article  PubMed  CAS  Google Scholar 

  32. Wilkinson PM, Antonopoulos M, Lahousen M et al (2006) Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 94:947–954

    Article  PubMed  CAS  Google Scholar 

  33. Straus DJ, Testa M, Riggs SA et al (2003) Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). Blood 102:497a

    Google Scholar 

  34. Steensma D, Molina R, Sloan J et al (2006) Phase III study of different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 24:1079–1089

    Article  PubMed  CAS  Google Scholar 

  35. Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486–2494

    Article  PubMed  CAS  Google Scholar 

  36. Boogaerts M, Coiffier B, Kainz C et al (2003) Impact of epoetin beta on quality of life with malignant disease. Br J Cancer 88:988–995

    Article  PubMed  CAS  Google Scholar 

  37. Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79–86

    Article  PubMed  CAS  Google Scholar 

  38. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220

    PubMed  CAS  Google Scholar 

  39. Canon JL, Vansteenkiste J, Bodoky G et al (2006) Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy. J Natl Cancer Inst 98:273–284

    Article  PubMed  CAS  Google Scholar 

  40. Waltzman R, Croot C, Justice JR et al (2005) Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcrog every 2 weeks) in anemic cancer patients receiving chemotherapy. Oncologist 10:642–650

    Article  PubMed  CAS  Google Scholar 

  41. Glaspy J, Vadhan-Raj S, Patel R et al (2006) Randomized comparison of every-2-weeks darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group trial. J Clin Oncol 24:2290–2297

    Article  PubMed  CAS  Google Scholar 

  42. Antonadou D, Cardamakis E, Puglisi M et al (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 37[Suppl 6]:S144

    Article  Google Scholar 

  43. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260

    Article  PubMed  CAS  Google Scholar 

  44. Goldberg P (2007) Danish researchers post long-awaited Aranesp results-ever so discretely. Interim analysis of Danish Head and Neck Cancer Group 10 trial. Cancer Lett 33:1–6

    Google Scholar 

  45. Wright J, Ung Y, Julian J et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032

    Article  PubMed  CAS  Google Scholar 

  46. Erythropoiesis Stimulating Agents: www.fdagov/medwatch/report.htm

  47. Safety Alert Aranesp (darbepoetin alfa). www.fda.gov/medwatch/safety/2007/Aranesp_DHCP_012707.htm

  48. Cancer and related anaemia. V.2007. www.nccn.org

  49. Khuri F (2007). Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356; 2445–2448

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología, Hospital Universitari Sant Joan de Reus, C/ Sant Joan, s/n, ES-43201, Reus, Spain

    A. Pelegrí

Authors
  1. A. Pelegrí
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Pelegrí.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pelegrí, A. Impact of erythropoietin treatment on the quality of life of oncologic patients. Clin Transl Oncol 9, 645–651 (2007). https://doi.org/10.1007/s12094-007-0117-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0117-1

Key words

Search

Navigation